Integrated Analyses Offer Molecular Insights to Tumor Subtypes
|
By LabMedica International staff writers Posted on 19 Jul 2018 |

Image: A histopathology of mixed germ cell tumor of the testes demonstrating the high-grade cytology, typical for embryonal carcinoma (Photo courtesy of Nephron).
The most common malignancy of young adult males of European descent are testicular germ cell tumors (TGCTs) of the type derived from germ cell neoplasia in situ (GCNIS). There are two major histologic types: pure classic seminoma and nonseminomatous germ cell tumors (NSGCTs).
Seminoma often has more indolent behavior, while NSGCT tends to occur at younger ages and confer higher mortality. TGCTs are now highly treatable, and overall relative survival of men with TGCTs exceeds 95%; however, survivors can experience devastating late effects of treatment.
An extensive team of scientists collaborating with those at University of North Carolina at Chapel Hill (Chapel Hill, NC, USA) studied 137 primary testicular germ cell tumors (TGCTs) using high-dimensional assays of genomic, epigenomic, transcriptomic, and proteomic features. The median age of diagnosis was 31 years, with a range of 14 to 67. Patient tumor histology was classified according to a consensus of expert pathologists. Molecular and genomic data were collected using reverse phase protein arrays (RPPAs), whole-exome DNA sequencing, RNA-seq, miRNA sequencing, DNA methylation arrays, and SNP arrays for copy number analysis.
The team reported that as expected, the 72 seminomas in this set clustered apart from the non-seminomatous tumors, based on these molecular data. They saw relatively limited mutation frequencies across most of the histological subtypes. Just three genes, KIT, KRAS, and NRAS, were significantly mutated in the TGCTs, and those recurrent mutations were limited to the seminoma subtype. Within seminomas, DNA methylation and immune infiltration differences also tended to coincide with the presence or absence of KIT gene mutations. Still other mutation frequency, ploidy, DNA methylation, and/or miRNA expression shifts corresponded with the remaining non-seminomatous subtypes.
In teratoma and yolk sac tumors, the group saw enhanced expression of a miRNA called miR-375 that is typically found at low levels in blood samples from healthy individuals. On the other hand, the embyronal carcinomas had higher-than-usual expression of miR-19 and other miRNAs, they noted, and were marked by DNA methylation at non-canonical cytosine sites.
The authors concluded the new TGCT molecular profiles afforded a more complete view of previously articulated hypotheses, provide additional insights into mechanisms of TGCT tumorigenesis, and identify possible new approaches to the treatment of TGCTs. Katherine Hoadley, PhD, is an assistant professor in Cancer Genetics and senior author of the study, said, “Integration of tumor characteristics and genomic and epigenomics data revealed distinctive molecular landscapes of TGCT histologic types, and identified previously unappreciated diversity within seminomas.” The study was published on June 12, 2018, in the journal Cell Reports.
Related Links:
University of North Carolina at Chapel Hill
Seminoma often has more indolent behavior, while NSGCT tends to occur at younger ages and confer higher mortality. TGCTs are now highly treatable, and overall relative survival of men with TGCTs exceeds 95%; however, survivors can experience devastating late effects of treatment.
An extensive team of scientists collaborating with those at University of North Carolina at Chapel Hill (Chapel Hill, NC, USA) studied 137 primary testicular germ cell tumors (TGCTs) using high-dimensional assays of genomic, epigenomic, transcriptomic, and proteomic features. The median age of diagnosis was 31 years, with a range of 14 to 67. Patient tumor histology was classified according to a consensus of expert pathologists. Molecular and genomic data were collected using reverse phase protein arrays (RPPAs), whole-exome DNA sequencing, RNA-seq, miRNA sequencing, DNA methylation arrays, and SNP arrays for copy number analysis.
The team reported that as expected, the 72 seminomas in this set clustered apart from the non-seminomatous tumors, based on these molecular data. They saw relatively limited mutation frequencies across most of the histological subtypes. Just three genes, KIT, KRAS, and NRAS, were significantly mutated in the TGCTs, and those recurrent mutations were limited to the seminoma subtype. Within seminomas, DNA methylation and immune infiltration differences also tended to coincide with the presence or absence of KIT gene mutations. Still other mutation frequency, ploidy, DNA methylation, and/or miRNA expression shifts corresponded with the remaining non-seminomatous subtypes.
In teratoma and yolk sac tumors, the group saw enhanced expression of a miRNA called miR-375 that is typically found at low levels in blood samples from healthy individuals. On the other hand, the embyronal carcinomas had higher-than-usual expression of miR-19 and other miRNAs, they noted, and were marked by DNA methylation at non-canonical cytosine sites.
The authors concluded the new TGCT molecular profiles afforded a more complete view of previously articulated hypotheses, provide additional insights into mechanisms of TGCT tumorigenesis, and identify possible new approaches to the treatment of TGCTs. Katherine Hoadley, PhD, is an assistant professor in Cancer Genetics and senior author of the study, said, “Integration of tumor characteristics and genomic and epigenomics data revealed distinctive molecular landscapes of TGCT histologic types, and identified previously unappreciated diversity within seminomas.” The study was published on June 12, 2018, in the journal Cell Reports.
Related Links:
University of North Carolina at Chapel Hill
Latest Molecular Diagnostics News
- Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
- Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
- Two-in-One DNA Analysis Improves Diagnostic Accuracy While Saving Time and Costs
- “Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
- New Tool Maps Chromosome Shifts in Cancer Cells to Predict Tumor Evolution
- Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
- Newly-Identified Parkinson’s Biomarkers to Enable Early Diagnosis Via Blood Tests
- New Blood Test Could Detect Pancreatic Cancer at More Treatable Stage
- Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
- New Tool Reveals Hidden Metabolic Weakness in Blood Cancers
- World's First Blood Test Distinguishes Between Benign and Cancerous Lung Nodules
- Rapid Test Uses Mobile Phone to Identify Severe Imported Malaria Within Minutes
- Gut Microbiome Signatures Predict Long-Term Outcomes in Acute Pancreatitis
- Blood Test Promises Faster Answers for Deadly Fungal Infections
- Blood Test Could Detect Infection Exposure History
- Urine-Based MRD Test Tracks Response to Bladder Cancer Surgery
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test
Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more
Blood Test Detects Early-Stage Cancers by Measuring Epigenetic Instability
Early-stage cancers are notoriously difficult to detect because molecular changes are subtle and often missed by existing screening tools. Many liquid biopsies rely on measuring absolute DNA methylation... Read more
“Lab-On-A-Disc” Device Paves Way for More Automated Liquid Biopsies
Extracellular vesicles (EVs) are tiny particles released by cells into the bloodstream that carry molecular information about a cell’s condition, including whether it is cancerous. However, EVs are highly... Read more
Blood Test Identifies Inflammatory Breast Cancer Patients at Increased Risk of Brain Metastasis
Brain metastasis is a frequent and devastating complication in patients with inflammatory breast cancer, an aggressive subtype with limited treatment options. Despite its high incidence, the biological... Read moreHematology
view channel
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Fast and Easy Test Could Revolutionize Blood Transfusions
Blood transfusions are a cornerstone of modern medicine, yet red blood cells can deteriorate quietly while sitting in cold storage for weeks. Although blood units have a fixed expiration date, cells from... Read more
Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
High-volume hemostasis sections must sustain rapid turnaround while managing reruns and reflex testing. Manual tube handling and preanalytical checks can strain staff time and increase opportunities for error.... Read more
High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
Blood clotting is essential for preventing bleeding, but even small imbalances can lead to serious conditions such as thrombosis or dangerous hemorrhage. In cardiovascular disease, clinicians often struggle... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channel
Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read moreAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read moreTechnology
view channel
Robotic Technology Unveiled for Automated Diagnostic Blood Draws
Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
ADLM Launches First-of-Its-Kind Data Science Program for Laboratory Medicine Professionals
Clinical laboratories generate billions of test results each year, creating a treasure trove of data with the potential to support more personalized testing, improve operational efficiency, and enhance patient care.... Read moreAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channelNew Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing
Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
AI-Powered Cervical Cancer Test Set for Major Rollout in Latin America
Noul Co., a Korean company specializing in AI-based blood and cancer diagnostics, announced it will supply its intelligence (AI)-based miLab CER cervical cancer diagnostic solution to Mexico under a multi‑year... Read more
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







